Bionik Laboratories(BNKL)
$0.100.00 (0.00%)
BNKL
Bionik Laboratories financials statements
$0.10
At close:0.00 (0.00%)
Bionik Laboratories (BNKL) Ratios
9 Followers
Bionik Laboratories Ratios
BNKL's free cash flow for Q4 2023 was $-757.70K. For the 2023 fiscal year, BNKL's free cash flow was decreased by $-752.00 and operating cash flow was $-756.94K. See a summary of the company’s cash flow.
| Ratios | Mar 23 | Mar 22 | Mar 21 | Jun 20 | Mar 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.20 | 3.07 | 0.84 | 1.12 | 1.15 |
| Quick Ratio | 0.75 | 2.27 | 0.67 | 0.92 | 1.02 |
| Cash Ratio | 0.19 | 1.33 | 0.15 | 0.44 | 0.14 |
| Solvency Ratio | -0.98 | -5.89 | -2.44 | -4.72 | -3.12 |
| Operating Cash Flow Ratio | -1.47 | -2.78 | -1.13 | -1.74 | -2.82 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -1.77 | -4.36 | 0.00 |
| Net Current Asset Value | $ -2.23M | $ 2.84M | $ -2.07M | $ 626.92K | $ 479.41K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.72 | 0.00 | 0.42 | 0.11 | 0.00 |
| Debt-to-Equity Ratio | -1.47 | 0.00 | 1.13 | 0.16 | 0.00 |
| Debt-to-Capital Ratio | 3.13 | 0.00 | 0.53 | 0.14 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 4.18 | 0.00 | 0.25 | 0.00 | 0.00 |
| Financial Leverage Ratio | -2.05 | 1.60 | 2.68 | 1.39 | 1.12 |
| Debt Service Coverage Ratio | -44.57 | -11.49 | -4.32 | -10.82 | -2.12 |
| Interest Coverage Ratio | -45.03 | -5.78 | -15.19 | -61.82 | -2.23 |
| Debt to Market Cap | 0.78 | 0.00 | 0.29 | 0.25 | 0.00 |
| Interest Debt Per Share | 0.36 | 0.14 | 0.80 | 0.51 | 1.38 |
| Net Debt to EBITDA | -0.42 | 0.21 | -0.24 | 0.01 | 0.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.83% | 74.84% | 77.41% | 58.51% | 49.78% |
| EBIT Margin | -268.05% | -752.35% | -1107.33% | -1153.30% | -224.57% |
| EBITDA Margin | -264.55% | -744.29% | -1091.43% | -1135.62% | -213.84% |
| Operating Profit Margin | -267.29% | -374.70% | -515.76% | -522.25% | -224.59% |
| Pretax Profit Margin | -273.99% | -817.14% | -1141.29% | -1161.75% | -325.21% |
| Net Profit Margin | -273.99% | -817.14% | -1141.29% | -1157.95% | -325.20% |
| Continuous Operations Profit Margin | -273.99% | -817.14% | -1141.29% | -1161.75% | -325.21% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 99.67% | 100.00% |
| EBT Per EBIT | 102.51% | 218.08% | 221.28% | 222.45% | 144.81% |
| Return on Assets (ROA) | -147.11% | -222.59% | -155.02% | -134.66% | -34.41% |
| Return on Equity (ROE) | 301.48% | -355.56% | -415.13% | -187.24% | -38.51% |
| Return on Capital Employed (ROCE) | -458.24% | -149.90% | -131.22% | -84.45% | -26.60% |
| Return on Invested Capital (ROIC) | -448.84% | -149.90% | -84.28% | -73.04% | -26.60% |
| Return on Tangible Assets | -153.20% | -222.59% | -386.23% | -416.92% | -267.80% |
| Earnings Yield | -179.11% | -474.93% | -106.24% | -302.49% | -105.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.98 | 4.63 | 2.64 | 2.49 | 2.04 |
| Payables Turnover | 1.46 | 1.05 | 0.59 | 1.04 | 1.42 |
| Inventory Turnover | 0.79 | 0.27 | 0.39 | 0.84 | 4.02 |
| Fixed Asset Turnover | 4.08 | 13.96 | 12.75 | 13.97 | 16.86 |
| Asset Turnover | 0.54 | 0.27 | 0.14 | 0.12 | 0.11 |
| Working Capital Turnover Ratio | 1.01 | 1.05 | -67.68 | 3.89 | -1.04 |
| Cash Conversion Cycle | 305.10 | 1087.84 | 459.52 | 229.27 | 12.83 |
| Days of Sales Outstanding | 91.61 | 78.76 | 138.21 | 146.59 | 179.23 |
| Days of Inventory Outstanding | 463.11 | 1356.58 | 936.98 | 432.86 | 90.83 |
| Days of Payables Outstanding | 249.63 | 347.51 | 615.67 | 350.18 | 257.23 |
| Operating Cycle | 554.72 | 1435.34 | 1075.19 | 579.44 | 270.06 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.49 | -0.71 | -0.90 | -2.03 | -3.91 |
| Free Cash Flow Per Share | -0.49 | -0.71 | -0.90 | -2.07 | -3.95 |
| Dividend Paid and CapEx Coverage Ratio | -389.62 | -331.78 | -1155971.50 | -56.77 | -90.71 |
| Capital Expenditure Coverage Ratio | -389.62 | -331.78 | -1155971.50 | -56.77 | -90.71 |
| Operating Cash Flow Coverage Ratio | -1.40 | 0.00 | -1.24 | -4.36 | 0.00 |
| Operating Cash Flow to Sales Ratio | -1.88 | -3.26 | -3.87 | -4.21 | -2.84 |
| Free Cash Flow Yield | -122.66% | -189.81% | -36.06% | -111.89% | -92.94% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.56 | -0.21 | -0.94 | -0.33 | -0.95 |
| Price-to-Sales (P/S) Ratio | 1.53 | 1.72 | 10.74 | 3.83 | 3.09 |
| Price-to-Book (P/B) Ratio | -1.68 | 0.75 | 3.91 | 0.62 | 0.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.82 | -0.53 | -2.77 | -0.89 | -1.08 |
| Price-to-Operating Cash Flow Ratio | -0.82 | -0.53 | -2.77 | -0.91 | -1.09 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.01 | 0.02 | -0.01 | 0.01 |
| Enterprise Value Multiple | -0.99 | -0.02 | -1.22 | -0.33 | -1.38 |
| Enterprise Value | 4.75M | 200.13K | 15.93M | 8.05M | 9.60M |
| EV to EBITDA | -0.99 | -0.02 | -1.22 | -0.33 | -1.38 |
| EV to Sales | 2.63 | 0.16 | 13.35 | 3.74 | 2.96 |
| EV to Free Cash Flow | -1.40 | -0.05 | -3.45 | -0.87 | -1.03 |
| EV to Operating Cash Flow | -1.40 | -0.05 | -3.45 | -0.89 | -1.04 |
| Tangible Book Value Per Share | -0.26 | 0.50 | -0.39 | 0.18 | 0.28 |
| Shareholders’ Equity Per Share | -0.24 | 0.50 | 0.64 | 2.99 | 11.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.26 | 0.22 | 0.23 | 0.48 | 1.37 |
| Net Income Per Share | -0.72 | -1.78 | -2.66 | -5.60 | -4.47 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.09 | 1.03 | 1.01 | 1.45 |
| Research & Development to Revenue | 0.50 | 0.78 | 1.25 | 1.81 | 0.98 |
| SG&A to Revenue | 1.62 | 2.20 | 3.83 | 2.78 | 1.61 |
| Stock-Based Compensation to Revenue | 0.21 | 0.34 | 0.69 | 0.83 | 0.42 |
| Income Quality | 0.68 | 0.40 | 0.34 | 0.36 | 0.87 |
Currency in USD

